Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Article - 11/06/2019 A portrait by Harald Zur Hausen

    New pathogens in beef and cow's milk contributing to the risk of cancer

    A team of researchers led by Nobel laureate Prof. Dr. med. Dr. h.c. mult. Harald zur Hausen has discovered a new type of infectious agent in dairy and meat products produced from European cattle that increases the risk for colon and breast cancer. These so-called Bovine Meat and Milk Factors (BMMFs) are small DNA molecules that are similar in sequence to both bacterial plasmids and certain viruses.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-pathogens-in-beef-and-cows-milk-contributing-to-the-risk-of-cancer
  • Press release - 09/12/2021

    New research project in mathematical oncology

    A new interdisciplinary research project aims to uncover information that can help decode hereditary colon cancer with the aid of mathematical models. Mathematicians and tumour biologists of Heidelberg University, the Heidelberg Institute for Theoretical Studies, Heidelberg University Hospital, and the German Cancer Research Center are collaborating on the project.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-research-project-mathematical-oncology
  • Press release - 03/09/2025

    Therapeutic vaccination against HPV-related tumors: Nanoparticles make the difference

    Researchers from the German Cancer Research Center (DKFZ) have collaborated with the SILVACX project group at Heidelberg University to develop a therapeutic vaccination concept that can mobilize the immune system to target cancer cells. The team showed that virus peptides coupled to silica nanoparticles can elicit effective T-cell responses against HPV-related tumors.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/therapeutic-vaccination-against-hpv-related-tumors-nanoparticles-make-difference
  • Press release - 19/05/2025

    How the Epstein-Barr virus promotes its spread in the body

    Many people are infected with the Epstein-Barr virus (EBV), and most are unaware of it. However, EBV can sometimes cause cancer, and this pathogen also appears to play an important role in multiple sclerosis and other autoimmune diseases. Researchers have discovered that EBV increases the ability of infected immune cells to migrate. In this way, the pathogen promotes its spread in the body – a discovery that may have therapeutic implications.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-epstein-barr-virus-promotes-its-spread-body
  • Peptide-based COVID-19 vaccine - 21/04/2022 A 96-well analysis plate with depressions of varying darkness is shown, held up by two gloved hands.

    CoVac-1: T-cell activator against COVID-19

    Current vaccines against COVID-19 aim at forming neutralising antibodies that prevent the virus from penetrating the host cells. Since people with impaired B-cell immune responses – which can also occur in cancer or autoimmune diseases – are not able to do this, researchers at the University of Tübingen have developed the peptide-based T-cell activator CoVac-1, which promises broad and long-term immunity.

    https://www.gesundheitsindustrie-bw.de/en/article/news/covac-1-t-cell-activator-against-covid-19
  • Translational oncology - 26/05/2020 NCT_181204_3435.jpg

    Translation: driver of cancer medicine

    The fight against cancer is a pressing issue. Although technological advances in the treatment, prevention and early detection of cancer have improved over the past few decades, the number of people affected is increasing. Cancer medicine now wants to counteract this by joining forces with other players involved in the field.

    https://www.gesundheitsindustrie-bw.de/en/article/news/translation-driver-cancer-medicine
  • Press release - 31/01/2024

    Precursor of Cholesterol Protects Cancer Cells From Cell Death and Makes them Aggressive

    A precursor of cholesterol can protect cancer cells from a form of cell death known as ferroptosis. Scientists of the University of Würzburg, the German Cancer Research Center (DKFZ), and the Stem Cell Institute HI-STEM* published this finding in the journal Nature. The results opens up exciting prospects for further improving the treatment of cancer and other diseases associated with oxidative stress and ferroptosis.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cholesterin-vorstufe-schuetzt-krebszellen-vor-zelltod-und-macht-sie-aggressiver
  • Press release - 24/11/2025

    Shield against metastases and genetically protected CAR-T cells: Double honor for Mirco Julian Friedrich

    Physician and cancer researcher Mirco Julian Friedrich from the German Cancer Research Center (DKFZ), the stem cell research institute HI-STEM*, and Heidelberg University Hospital (UKHD) has received two awards for two independent research projects: his novel approach to preventing liver metastases and his research on T cells, which he modifies to better protect them from attacks by natural killer cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/shield-against-metastases-and-genetically-protected-car-t-cells-double-honor-mirco-julian-friedrich
  • Climate protection is health protection - 26/02/2026 Hände halten die Erdkugel behutsam.

    Planetary health: advancing human health in the era of climate change

    Heatwaves, deteriorating air quality and extreme weather events are reshaping our living conditions. The climate and environmental crisis represent one of the greatest threats to human health. Are we prepared? Adaptation strategies, heat action plans and public education are essential to protecting health in a changing climate.

    https://www.gesundheitsindustrie-bw.de/en/article/news/planetary-health-advancing-human-health-era-climate-change
  • Press release - 16/06/2026

    Kickoff for the EU-Pathfinder Project HEARTCORE at the NMI

    It goes without saying that new drug compounds should place as little strain on the heart as possible. But how can potential effects be reliably predicted? Researchers from the NMI, Hannover Medical School (project lead), the Universitat Politecnica de Valencia, and industry partners Multi Channel Systems and Foresee Biosystems are tackling this challenge in the new HEARTCORE project.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/kickoff-eu-pathfinder-project-heartcore-nmi
  • Press release - 14/03/2022

    Do gut bacteria influence treatment success of CAR-T cell therapies?

    Through the Endeavour Awards, the Mark Foundation supports research projects that bring together scientists from different disciplines to advance the prevention, diagnosis and treatment of cancer. One of the only four Endeavour Awards presented this year goes to a project coordinated by scientists from the German Cancer Research Center (DKFZ).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/do-gut-bacteria-influence-treatment-success-car-t-cell-therapies
  • Atriva Therapeutics - 21/10/2020 Kulturschalen mit blau angefärbten Zellen, zu denen das neue Coronavirus (SARS CoV-2) gegeben wurde. Die mit dem Wirkstoff ATR-002 von Atriva Therapeutics behandelten Zellen (rechte Reihen) zeigen keine weißen Löcher im Zellrasen und somit keine Zellzerstörung.

    COVID-19 pioneer drug in Phase II clinical trial - with double the power

    The effective treatment of people with severe COVID-19 is a major goal during the corona pandemic. ATR-002, an oral small molecule that targets RNA viruses such as influenza virus and SARS-CoV-2, has a dual effect: it impairs viral propagation and also has an immunomodulatory effect. And what’s more, due to its unique cellular mechanism of action, the efficacy of Atrivia Therapeutics’ drug candidate is not reduced by virus mutations and…

    https://www.gesundheitsindustrie-bw.de/en/article/news/covid-19-pioneer-drug-phase-ii-clinical-trial-double-power
  • Project BlindZero - 03/08/2023 The two researchers in the laboratory in front of the 3D printer and with a Petri dish with the cornea in their hands.

    Hope for patients with eye diseases: human cornea from 3D printers

    Thousands of cornea transplants are performed every year. However, donors are rare and the procedure is not always without complications. Researchers at the University of Heidelberg are developing an innovative technique in the project BlindZero. It involves ‘printing’ human corneas directly onto patients’ eyes using 3D bioprinting. The reprogrammed genetically engineered cells used for this purpose are not expected to cause a rejection reaction.

    https://www.gesundheitsindustrie-bw.de/en/article/news/hope-patients-eye-diseases-human-cornea-3d-printers
  • New polymer for wound care - 09/01/2025 Das Bild zeigt einen Kühlakku, der gegen die Arminnenseite gehalten wird

    Thermoresponsive adhesive for pain-free removal of wound dressings

    Plasters or wound dressings can only perform their intended function if they adhere securely to the skin. However, they are often painful to remove, and in some cases, damage delicate newly formed tissue. Researchers at the University of Freiburg have developed an innovative polymer that adheres reliably at body temperature but can be easily and painlessly removed, leaving no residue, after being cooled.

    https://www.gesundheitsindustrie-bw.de/en/article/news/thermoresponsive-adhesive-pain-free-removal-wound-dressings
  • Novel coronavirus outbreak - a status report on recent developments - 04/03/2020 Coronavirus, Modell

    Waiting for a SARS-CoV-2 vaccine

    Researchers around the world are working frantically on the development of a vaccine against the new coronavirus. A project by the Tübingen-based biotechnology company CureVac, funded by the Coalition for Epidemic Preparedness Innovations (CEPI), uses the company’s technology platform for mRNA-based vaccines to accelerate vaccine development, thus contributing to the future prevention of the disease.

    https://www.gesundheitsindustrie-bw.de/en/article/news/Waiting-for-a-SARS-CoV-2-vaccine
  • Press release - 11/03/2021

    Researchers recommend earlier start of breast cancer screening with family history of ovarian cancer

    Women have an increased risk of breast cancer if they have a family history of this disease. However, the risk may also be higher if first-degree family members have another type of cancer, according to a study by a team of scientists and physicians from the National Center for Tumor Diseases (NCT) Heidelberg, the German Cancer Research Center (DKFZ) and Heidelberg University Hospital (UKHD), as well as international colleagues.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/researchers-recommend-earlier-start-breast-cancer-screening-family-history-ovarian-cancer
  • Expert interview - 31/08/2021 A coloured circular representation of different types of scenarios: 1a-c: Gradual evolution of the healthcare system, 2 a-b: Healthcare system change arises from cultural evolution, 3a-c: Healthcare system change arises from innovative technologies and cultural awareness change, 4a-b: Technology-driven healthcare system change.

    Health Data Scenarios - many possibilities for the future?

    The digitization of healthcare is progressing slowly but steadily. In addition to simple telemedical applications, data such as electronic patient records are forming the basis of digitization. The ‘Health Data Scenarios’ project aims to model the future of healthcare data by using scenarios. Lucas Scherdel, Healthcare Innovation Director at DayOne, and Dr. Alexander Fink, founder and CEO of ScMI AG, explain how this will work.

    https://www.gesundheitsindustrie-bw.de/en/article/news/health-data-scenarios-many-possibilities-future
  • Press release - 22/01/2026

    NAKO study confirms link between smoking and depression

    A research group led by the Central Institute of Mental Health in Mannheim has confirmed for the first time within the German National Cohort an association between cigarette consumption and depression. The findings show that depression occurs more frequently over the lifetime of current and former smokers than among those who have never smoked.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nako-study-confirms-link-between-smoking-and-depression
  • Inside the fight against COVID-19 - 28/10/2020 Apogenix_Asunercept_COVID-19_Teaser.png

    A new immunotherapeutic agent for treating severe COVID-19 cases

    Apogenix, a Heidelberg-based biopharmaceutical company specialising in innovative immunotherapeutics, has initiated a Phase II clinical trial with asunercept, the company’s lead drug candidate for treating severe cases of COVID-19. The fusion protein blocks the CD95-ligand-mediated death of epithelial cells in the lung and thus prevents damage to the organ.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-immunotherapeutic-agent-treating-severe-covid-19-cases
  • Press release - 03/01/2024

    Reprogrammed fat cells support tumor growth

    Mutations of the tumor suppressor p53 not only have a growth-promoting effect on the cancer cells themselves, but also influence the cells in the tumor's microenvironment. Scientists at the Weizmann Institute in Israel and at the German Cancer Research Center (DKFZ) have now shown that p53-mutated mouse breast cancer cells reprogram fat cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/reprogrammed-fat-cells-support-tumor-growth
  • Press release - 05/09/2024

    Cohesion at the cellular level: flexible yet stable

    Research teams from the Universities of Konstanz and Potsdam are analyzing how proteins work together to enable our cells to both stick and move. The marker protein paxillin is at the centre of their interest.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cohesion-cellular-level-flexible-yet-stable
  • Press release - 16/12/2025

    New measures to make EU health sector more innovative, competitive and resilient

    The European Commission has today proposed an ambitious package of measures to improve the health of EU citizens, while ensuring the long-term resilience and competitiveness of the health sector.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-measures-make-eu-health-sector-more-innovative-competitive-and-resilient
  • Press release - 07/08/2026

    Can Protein Building Blocks Protect Against Vascular and Kidney Damage?

    Researchers from the Medical Faculty Heidelberg, the Medical Faculty Mannheim, and the Centre for Organismal Studies at Heidelberg University have launched a new research project investigating so-called dipeptides. The consortium aims to determine which dipeptides have the strongest protective effects and how they could be harnessed in future therapies for vascular and kidney diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/can-protein-building-blocks-protect-against-vascular-and-kidney-damage
  • Lab-on-a-chip - 11/11/2020 Bild_3.jpg

    Microfluidic platform for the best possible cancer therapy

    Every tumour and every patient is different, and there are individual reactions to drugs as well as the problem of resistance. Patient-specific cancer treatments require innovative and cost-effective approaches. The TheraMe! consortium has developed a novel instrument: a combination of microfluidic experiments and mathematical modelling for use in cancer precision medicine to prevent incorrect therapy options.

    https://www.gesundheitsindustrie-bw.de/en/article/news/microfluidic-platform-best-possible-cancer-therapy
  • Press release - 07/02/2023

    Hertie Foundation establishes new institute combining artificial intelligence and neuroscience

    This month marks the launch of an outstanding project integrating artificial intelligence (AI) and neuromedicine – the Hertie Institute for Artificial Intelligence in Brain Health (Hertie AI). Founded on February 1 at the Medical Faculty of the University of Tübingen, it will be the first institute in Germany to research the prevention and early diagnosis of diseases of the nervous system using artificial intelligence methods.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/hertie-stiftung-gruendet-neues-institut-das-kuenstliche-intelligenz-und-neurowissenschaften-verbindet
  • Dossier - 08/09/2026 The image shows the upper body of a person wearing a lab coat and a stethoscope, with a heart drawn in their open hands, featuring medical symbols.

    AI and robotics are shaping the future of medicine

    Artificial intelligence and robotics are playing an increasingly important role in healthcare, as in many other areas of life. They offer considerable potential to improve medical care, but require an ethically responsible approach.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/ai-and-robotics-are-shaping-future-medicine
  • Article - 29/04/2021 aufbau-antikoerper.jpg

    Nanobodies for determining neutralising antibodies after corona infection

    After contact with a pathogen, ideally our immune system generates neutralising antibodies to prevent a future infection. With NeutrobodyPlex, scientists from Reutlingen and Tübingen have developed a highly specific test procedure based on single-domain antibodies (nanobodies) that can be used to easily and reliably determine the quality of the immune response against the novel coronavirus.

    https://www.gesundheitsindustrie-bw.de/en/article/news/nanobodies-determining-neutralising-antibodies-after-corona-infection
  • Press release - 25/09/2024

    How developmental signals can contribute to Genomic Mosaicism

    Certain developmental signals play a significant role in maintaining our genetic blueprints. They prevent alterations in the genome, known as mosaicism. The underlying biological mechanism helps the DNA to produce an identical copy of itself during cell division using the original genetic blueprint. However, it can also contribute to genomic mosaicism during nerve cell development.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-developmental-signals-can-contribute-genomic-mosaicism
  • Press release - 08/01/2026

    Award for EMG electrode research

    How modern medical technology can prevent serious consequences of surgical procedures is demonstrated by a recent internationally recognized scientific publication. The study “Validation of conductive resin as electrode material in neuromonitoring with 3D-printed probes” under the leadership of Drs. Kiese and Bucher was awarded at the ICST Conference in Japan and highlights a medical topic that is crucial for the quality of life of many people.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/award-emg-electrode-research
  • Press release - 08/05/2026

    The Plasticity of Malignant Brain Tumors as a Potential Therapeutic Approach: Sibylle Assmus Prize for Neuro-Oncology Awarded to Moritz Mall

    The ability of cancer cells to change their identity makes tumors such as glioblastoma particularly aggressive and resistant to treatment. Moritz Mall, of the German Cancer Research Center (DKFZ) and the Hector Institute for Translational Brain Research (HITBR), is investigating how this plasticity can be specifically restricted. His approach focuses on genetic “guardians” that suppress alternative cell programs.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/plasticity-malignant-brain-tumors-potential-therapeutic-approach-sibylle-assmus-prize-neuro-oncology-awarded-moritz-mall
  • Affimed GmbH - 01/07/2020 Schematische Darstellung der Kommunikation zwischen den Zellen der angeborenen und erworbenen Immunität. „innate cell engager“ aktivieren NK-Zellen und Makrophagen, die wiederum tumorspezifische T-Zellen stimulieren.

    "Innate cell engager" fighting against cancer

    In the fight against tumour cells, d Affimed GmbH from Heidelberg relies entirely on the weapons of the innate immune system. Affimed has developed special innate cell engagers, which are bispecific antibodies that recognise tumour cells and bring them together with natural killer cells and macrophages of the innate immune system, which then kill the tumour cells. Clinical trials using the AFM13 molecule are ongoing.

    https://www.gesundheitsindustrie-bw.de/en/article/news/innate-cell-engager-fighting-against-cancer
  • Start-up Actimi GmbH - 23/11/2022 The photo shows a body scale and the user interface of the app on the tablet. Furthermore, a bag and the ECG measuring device can be seen.

    Real-time telemonitoring of heart failure

    Improved quality of life for patients and lower costs for health insurers: these are the advantages of telemonitoring patients with advanced heart failure. The Stuttgart-based start-up Actimi offers an all-in-one platform for those who treat and those who suffer from the disease.

    https://www.gesundheitsindustrie-bw.de/en/article/news/real-time-telemonitoring-heart-failure
  • Article - 24/01/2019 The photo shows an ultra filtration system.

    Scientists to combat antibiotic-resistant bacteria in wastewater

    In Germany, around 1,500 tonnes of antibiotics per year are administered to humans and animals. As a result, more and more bacteria are developing resistance to common antibiotics. As part of HyReKA, a cooperative project funded by the BMBF, scientists led by Professor Thomas Schwartz from the KIT are investigating how antibiotic-resistant pathogens spread and how they can be prevented from doing so.

    https://www.gesundheitsindustrie-bw.de/en/article/news/scientists-to-combat-antibiotic-resistant-bacteria-in-wastewater
  • Cluster of the future - 25/11/2021 NanodiagBW_Teaser.png

    nanodiagBW: using nanopores to create completely new diagnostic possibilities

    Modern medicine has a wide range of molecular diagnostics at hand. In the next decade, this will increasingly be supplemented by prognostic methods. The BMBF Cluster of the Future finalist, nanodiag BW, is developing prognostic methods to identify epigenetic factors for diseases through a new type of bioanalytics – single molecule analysis in nanopores – which would make it possible to take personalised prevention approaches.

    https://www.gesundheitsindustrie-bw.de/en/article/news/nanodiagbw-using-nanopores-create-completely-new-diagnostic-possibilities
  • Reduced immunosuppression possible in transplantations - 05/06/2023 Group photo of the founding team. Two younger men in light blue shirts and short hair and a woman with long dark hair in a white turtleneck jumper can be seen.

    Modified immune cells produce donor-specific tolerance

    Traditionally, transplant recipients have had to take immunosuppressive medication for life to prevent organ rejection. However, there are considerable side effects involved. Using modified immune cells (MICs), TolerogenixX GmbH from Heidelberg has now managed to generate donor-specific tolerance in recipients of living kidney transplants without suppressing the overall immune system.

    https://www.gesundheitsindustrie-bw.de/en/article/news/modified-immune-cells-produce-donor-specific-tolerance
  • Press release - 27/02/2025

    EU Project: New Molecular Interventions against Virus Infections

    Targeted molecular interventions in the replication cycle and the immune recognition of viruses are intended to prevent viral entry into cells and virus replication. Scientists work on new approaches to combating highly dangerous viral diseases such as yellow fever or Lassa fever. The European Union is supporting the project over a period of five years to the tune of just under eight million euros.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/eu-project-new-molecular-interventions-against-virus-infections
  • Digital bone twin by OSORA medical - 04/05/2026 OSORA_Bild_2.jpg

    Fractures in focus: predicting rather than waiting

    Bone fractures are generally healed by the body without any issues. However, there are hundreds of thousands of cases each year in which a fracture either fails to heal or only does so slowly. To reduce the number of cases where this happens, a start-up called OSORA medical has developed methods to predict the healing process and, if necessary, make preventative adjustments.

    https://www.gesundheitsindustrie-bw.de/en/article/news/fractures-focus-predicting-rather-waiting
  • Dossier - 12/03/2012 One hand holds a cell culture plate with six different cell cultures

    Regenerative medicine makes use of patients own resources

    Die Regenerative Medizin bietet neue Therapieoptionen quer durch die ärztlichen Fachgebiete. Zumeist sind es zellbasierte Verfahren und sie werden häufig mit innovativen Biomaterialien kombiniert. Regenerative Therapien vereinen Know-how aus den Biowissenschaften mit moderner Medizintechnik und sie profitieren von den Fortschritten in den Ingenieur- und Materialwissenschaften.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/regenerative-medicine-makes-use-of-patients-own-resources
  • Press release - 07/05/2024

    Intermittent fasting protects against liver inflammation and liver cancer / Drug partially mimics fasting effects

    Fatty liver disease often leads to chronic liver inflammation and can even result in liver cancer. Scientists from the German Cancer Research Center (DKFZ) and the University of Tuebingen have now shown in mice that intermittent fasting can halt this development.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/intermittent-fasting-protects-against-liver-inflammation-and-liver-cancer-drug-partially-mimics-fasting-effects
  • Press release - 29/11/2022

    Prototype funding for two Konstanz projects

    Chemical building blocks from plastic waste; Reducing the risk of falls using virtual orientation aids: Konstanz chemists Manuel Häußler and Lukas Odenwald as well as sport scientist Lorenz Assländer receive Baden-Württemberg prototype funding for their transfer projects "Waste2DCA" and "Augmented Balance".

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/doppelter-erfolg-der-prototypenfoerderung
  • Press release - 23/06/2023

    The molecular control centre of our protein factories

    Researchers from Konstanz and Zurich have deciphered a biochemical mechanism that ensures that newly formed proteins are processed correctly when they leave the cell's own protein factories. This solves a decade-old puzzle in protein sorting.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-control-centre-our-protein-factories
  • Multiple sclerosis - 12/03/2020 Anatomie_des_menschlichen_Kopfes.jpg

    Direct application of biopharmaceuticals through the nose into the brain

    There is currently no cure for multiple sclerosis, the most common neurological autoimmune disease in humans. Biopharmaceuticals that can delay the course of the disease or diminish its effects are often prevented from being fully effective by the blood-brain barrier. A European consortium led by the Fraunhofer IGB, Stuttgart is developing a new technology that can transport an innovative active ingredient directly to the central nervous system.

    https://www.gesundheitsindustrie-bw.de/en/article/news/Direct-application-of-biopharmaceuticals-through-the-nose-into-the-brain
  • Press release - 24/07/2025

    The origin of evil: stem cell-like cells are the reason for relapses of blood cancer in children and adolescents

    Stem cell-like leukemia cells are responsible for relapses in children and adolescents with a certain type of blood cancer, T-ALL. Researchers at the Hopp Children's Cancer Center Heidelberg (KiTZ), the Molecular Medicine Partnership Unit and the German Cancer Research Center were able to show this in a study. The results could help to overcome resistance in this form of blood cancer and prevent relapses.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/origin-evil-stem-cell-cells-are-reason-relapses-blood-cancer-children-and-adolescents
  • Innovation for sustainable plastic packaging - 04/09/2024 LPP.jpg

    Liquid Plug & Play: eco-designed plastic packaging – not just for ultrasound gel

    In the healthcare industry tons of consumables such as ultrasound gel go to waste because packaging can’t be completely emptied. An invention called Liquid Plug & Play could offer a solution for the future. This innovation, which consists of a reusable outer shell and a disposable product pouch for viscous substances, can be completely emptied. It also prevents cross-contamination and offers many other benefits.

    https://www.gesundheitsindustrie-bw.de/en/article/news/liquid-plug-und-play-eco-designed-plastic-packaging-not-just-ultrasound-gel
  • Press release - 10/04/2026

    New study identifies clinically relevant changes in airway wall thickness in COPD and at-risk individuals

    A recent study published in the European Respiratory Journal provides important new insights into the early identification and monitoring of chronic obstructive pulmonary disease (COPD). The focus is on airway wall thickness as an imaging marker for structural remodeling processes in the lungs.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-study-identifies-clinically-relevant-changes-airway-wall-thickness-copd-and-risk-individuals
  • Press release - 26/05/2025

    Explainable artificial intelligence increases the accuracy and endurance of dermatologists in melanoma diagnosis

    Scientists at the German Cancer Research Center (DKFZ) have shown in an international eye-tracking study that dermatologists not only improve their diagnostic accuracy by using explainable artificial intelligence, but also show significantly less fatigue when assessing challenging cases. The researchers were able to demonstrate this by measuring a reduction in cognitive stress indicators.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/explainable-artificial-intelligence-increases-accuracy-and-endurance-dermatologists-melanoma-diagnosis
  • Press release - 03/09/2025

    Nature publication: Mechanical tensions as a driver of evolution

    When embryos grow, cells and tissue are constantly bumping into each other. This creates mechanical tensions that could endanger their development. A team from University of Hohenheim and the Japanese RIKEN Center have discovered that fly embryos have strategies to deal with this pressure. The different species have developed two different solutions. This ability to control mechanical tension could be a key to why so many body plans have evolved.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nature-publication-mechanical-tensions-driver-evolution
  • Expert interview on NTDs – part 1 - 11/04/2019 A picture of Carsten Köhler

    Neglected tropical diseases – Carsten Köhler: impulses from Baden-Württemberg

    More than one billion people worldwide suffer from neglected tropical diseases (NTDs). NTDs are mostly poverty-related infectious diseases that prevail in tropical countries due to lack of research and measures to detect, prevent and control them. Dr. Dr. Carsten Köhler reports on the political, economic and scientific contributions Germany and Baden-Württemberg can make to successfully change this situation.

    https://www.gesundheitsindustrie-bw.de/en/article/news/vernachlaessigte-tropenkrankheiten-carsten-koehler-impulse-aus-baden-wuerttemberg
  • Press release - 14/08/2024

    New vaccine against cervical cancer combines prophylactic and therapeutic activities

    Scientists at the German Cancer Research Center (DKFZ) have developed a completely new vaccination concept. The vaccine is inexpensive and protects mice against almost all cancer-causing HPV types. In addition to preventing new infections, the vaccine also triggers cellular immune responses against HPV-infected cells and may therefore also have a therapeutic effect against existing infections.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-vaccine-against-cervical-cancer-combines-prophylactic-and-therapeutic-activities
  • Press release - 24/04/2026

    New Medical Director of the Department of Nephrology

    Prof. Dr. Halbritter has served as the new Medical Director of the Department of Nephrology at the Medical Center – University of Freiburg since April 2026. With his expertise, he is enhancing care for patients with kidney disease: The goal is to prevent kidney failure through early diagnosis and the implementation of strategies to slow disease progression. For cases where kidney failure has already occurred, the focus is on organ replacement.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-medical-director-department-nephrology

Page 2 / 5

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2026
Website address: https://www.gesundheitsindustrie-bw.de/en/search